[ Novartis Forschungsstiftung – FreeNovation | Research funding on Systems Medicine ]

The Novartis Research Foundation (Novartis Forschungstiftung) has launched the 2019 FreeNovation thematic call for research projects on Systems medicine: From molecule to phenotype and better therapies.
 
Proposals must:

• Apply to at least one of the following key words:
  1. Data integration, modeling & simulation
  2. Analytics, diagnostics, imaging
  3. Physiology, pathology, pharmacology
• Relate to biomedical research with the ultimate aim to provide healthcare solutions for patients.
• Be unconventional and radical, with the potential to open up novel research directions and aiming beyond incremental innovation and discovery.
• Be particularly original and hard to fund by conventional funding programs due to the “unorthodox” character of the idea or absence of a long-standing academic reputation held by the researchers.
• NOT include commercial activities nor be influenced by commercial interests.

• PhD or equivalent qualification
• Employed at a reputable healthcare or healthcare-related organization, incl. university, university hospital or university of applied science in Switzerland throughout the duration of the grant.
• Interdisciplinary proposals from scientists inside or outside of traditional disciplines are welcome.
• Max. 2 applicants → co-applicants may together submit a single proposal. Alternatively, they can submit two proposals, but tag them as connected (although connected proposals will be reviewed separately, the benefits of the collaboration will be factored into the evaluation).

• Please fill out the Institutional Support Letter template available in the EPFL Toolkit , have it signed by the Dean and, if applicable, by the Director of the Institute and the Head of Unit, and send it to [email protected] by 5 April 2019 for the institutional signature.
• Submit your proposal by 14 April 2019, 23:59 CET via FreeNovation online application portal.
• Proposals will be reviewed anonymously to encourage young scientists and unconventional ideas by an international review committee chaired by Prof. Gerd Folkers (ETHZ) with 6 academic and 3 Novartis scientists, who are experts in the field.
• Decision: mid July 2019.